詠竹坊

Medical Device Maker Highlights China Risk as Chinese U.S. IPOs Resume

Meihua International’s updated prospectus includes new section on Beijing’s intent to ‘exert more oversight and control’ over overseas Chinese listings

This article only represents the author's own views.

It’s a new week, with yet more signs that the China-U.S. IPO pipeline is slowly creaking back to life. This time it’s a relatively small IPO by a medical device maker named Meihua International Medical Technologies Co. Ltd. that’s making headlines with the company’s latest filing for a plan to raise a modest $57 million.

At the same time, two new listings we wrote about last week have also moved forward. The first saw drug maker LianBio’s (LIAN.US) shares fizzle in their trading debut, falling 14% on their first trading day, as it became the first major New York listing by a Chinese company since a halt in July. The second saw hotel operator Atour Lifestyle Holdings Ltd. (ATAT.US) file an updated prospectus for its plan to raise about $350 million.

您已閱讀13%(809字),剩餘87%(5515字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×